Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug
Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn’s disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2015/456895 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561021461463040 |
|---|---|
| author | Cristiana Perrotta Paolo Pellegrino Eliana Moroni Clara De Palma Davide Cervia Piergiorgio Danelli Emilio Clementi |
| author_facet | Cristiana Perrotta Paolo Pellegrino Eliana Moroni Clara De Palma Davide Cervia Piergiorgio Danelli Emilio Clementi |
| author_sort | Cristiana Perrotta |
| collection | DOAJ |
| description | Inflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn’s disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents. |
| format | Article |
| id | doaj-art-7635e53c762346c8980c0592380d6b40 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-7635e53c762346c8980c0592380d6b402025-02-03T01:26:14ZengWileyGastroenterology Research and Practice1687-61211687-630X2015-01-01201510.1155/2015/456895456895Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old DrugCristiana Perrotta0Paolo Pellegrino1Eliana Moroni2Clara De Palma3Davide Cervia4Piergiorgio Danelli5Emilio Clementi6Unit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, ItalyUnit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, ItalyUnit of General Surgery, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, ItalyUnit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, ItalyUnit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, ItalyUnit of General Surgery, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, ItalyUnit of Clinical Pharmacology, National Research Council-Institute of Neuroscience, Department of Biomedical and Clinical Sciences “Luigi Sacco”, University Hospital “Luigi Sacco”, Università di Milano, 20157 Milan, ItalyInflammatory bowel disease (IBD) comprises several conditions with chronic or recurring immune response and inflammation of the gastrointestinal apparatus, of which ulcerative colitis and Crohn’s disease are the commonest forms. This disease has a significant prevalence and it is of an unknown aethiology. Five-aminosalicylic acid (5-ASA) and its derivatives are among the oldest drugs approved for the treatment of the IBD. In this review we reapprise aspects of 5-ASA mechanism of action, safety, and efficacy that in our opinion make it a valuable drug that can be fruitfully tailored in personalised treatments as a therapeutic option alongside other immune-modifying agents.http://dx.doi.org/10.1155/2015/456895 |
| spellingShingle | Cristiana Perrotta Paolo Pellegrino Eliana Moroni Clara De Palma Davide Cervia Piergiorgio Danelli Emilio Clementi Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug Gastroenterology Research and Practice |
| title | Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug |
| title_full | Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug |
| title_fullStr | Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug |
| title_full_unstemmed | Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug |
| title_short | Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug |
| title_sort | five aminosalicylic acid an update for the reappraisal of an old drug |
| url | http://dx.doi.org/10.1155/2015/456895 |
| work_keys_str_mv | AT cristianaperrotta fiveaminosalicylicacidanupdateforthereappraisalofanolddrug AT paolopellegrino fiveaminosalicylicacidanupdateforthereappraisalofanolddrug AT elianamoroni fiveaminosalicylicacidanupdateforthereappraisalofanolddrug AT claradepalma fiveaminosalicylicacidanupdateforthereappraisalofanolddrug AT davidecervia fiveaminosalicylicacidanupdateforthereappraisalofanolddrug AT piergiorgiodanelli fiveaminosalicylicacidanupdateforthereappraisalofanolddrug AT emilioclementi fiveaminosalicylicacidanupdateforthereappraisalofanolddrug |